Amneal launches PEMRYDI RTU, ready-to-use version of pemetrexed, oncology injectable medicine

Amneal Pharmaceuticals announced the launch of PEMRYDI RTU, the first and only ready-to-use presentation of pemetrexed for injection. This product does not require reconstitution, dilution, or refrigeration, which is different than other versions of pemetrexed for injection.

PEMRYDI RTU injectable is available in two vial sizes: 100mg/10mL and 500 mg/50mL.

PEMRYDI RTU is indicated, in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberration and for initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

According to IQVIA, US annual sales for pemetrexed for the 12 months ended February 2024 were $287 million.